$4.24
+0.37 (+9.56%)
Open$3.92
Previous Close$3.87
Day High$4.70
Day Low$3.92
52W High$31.26
52W Low$20.39
Volume—
Avg Volume526.4K
Market Cap52.17M
P/E Ratio—
EPS$-1.85
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+559.0% upside
Current
$4.24
$4.24
Target
$27.94
$27.94
$24.18
$27.94 avg
$39.76
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.10M | 7.51M | 6.99M |
| Net Income | -2,253,266 | -2,377,750 | -1,909,981 |
| Profit Margin | -27.8% | -31.6% | -27.3% |
| EBITDA | -3,375,106 | -3,186,219 | -2,905,098 |
| Free Cash Flow | -1,035,116 | -1,228,536 | -1,335,718 |
| Rev Growth | +18.0% | -0.1% | +13.5% |
| Debt/Equity | 0.78 | 0.76 | 0.84 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |